{"id":"W3011435761","doi":"10.1016/j.ejca.2020.02.021","title":"Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":110,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Sandoz; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; InflaRx; Les Laboratories Pierre Fabre; Helsinn; OncoSec Medical; Roche; CureVac; Regeneron Pharmaceuticals; Novartis; Alcedis; Bristol-Myers Squibb; Sanofi; Merck; Boehringer Ingelheim; Amgen; Array BioPharma","keywords":"Medicine; Oncology; Melanoma; Blockade; Clinical trial; Internal medicine; Survival analysis; Progression-free survival; MEK inhibitor; Kinase; Cancer research; Overall survival; MAPK/ERK pathway; Biology; Receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007860598,0.0005446045,0.001383741,0.0004155546,0.0001111313,0.0007011032,0.0004294164,0.0005904858,0.001221707],"category_scores_gemma":[0.0009895505,0.00009948004,0.001037826,0.0008182224,0.0001840118,0.000502444,0.000258111,0.001282184,0.0002546485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000501294,"about_ca_system_score_gemma":0.0004807509,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001116525,"about_ca_topic_score_gemma":0.004212488,"domain_scores_codex":[0.9998857,0.00002421207,0.00002150648,0.00001967448,0.00003193523,0.00001707761],"domain_scores_gemma":[0.9994679,0.0003125075,0.000091382,0.00001121627,0.00007713174,0.00003985994],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.004337714,0.0001359147,0.00782114,0.007296914,0.001298008,0.0002896086,0.00006505895,0.0009829755,0.001985818,0.0009899972,0.02589328,0.9489035],"study_design_scores_gemma":[0.00179994,0.00812283,0.148385,0.01194459,0.01317952,0.00448329,0.000303396,0.001618681,0.002358259,0.003491941,0.8041818,0.0001307117],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.01352378,0.9800466,0.0002578576,0.002092056,0.0008925952,0.00001168709,0.0003908095,0.00001463848,0.002770016],"genre_scores_gemma":[0.08149244,0.9078771,0.0008752464,0.003684574,0.002767929,0.00003905255,0.001144022,0.00001231446,0.002107135],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.001383741,"threshold_uncertainty_score":0.004157186,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009071601066493962,"score_gpt":0.229577607853554,"score_spread":0.2205060067870601,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}